The Pathway Cell Line™ delivers high titers for almost all types of proteins. We consistently deliver titers from 4-9 g/l. Even for difficult to express proteins.

The Pathway Cell Line™ can express:

• mAbs
• recombinant proteins
• fusion proteins
• bispecifics
• biosimilars
• antibody fragement
• among other biologics format

Our cell line has an excellent track record of scalability and stability and has been used to produce clinical material in 2000 L bioreactors. It is based in the CHO-K1 cell line, which has been used to produce for hundreds of biologics globally.

Stable, repeatable and highly viable process

The graph to the right shows how Pathway CHO cell viability over 14 days in 2x3, 2x10 L STR. The cell line has been run in 2000 L bioreactors with proven scalability and can be used for pre-clinical, clinical or commercial production.

Our timeline allows for the production of pre-clinical material and start of process development, if desired, from 3 weeks.

We utilize the latest equipment throughout the process including:

• Ambr15 - an automated high throughput mini bioreactor system
• Cellavista - an Ultra high throughput imaging system
• Cytomine - single cell analysis to ensure proof of monoclonality
• Octet - allows rapid titer measurements

Combined this allows us to screen upto 2000 clones a day

• Pure fee for service with no license, milestone, royalty or success fees
• Industry competitive prices
• Stable pools ready in 3 weeks for pre-clinical material or process development start
• Rapid timeline to proven monoclonal RCBs
• High titers from 4 - 9g/l
• Over 50 cell lines produced with multiple lines used in clinical trials
• Suitable for mAbs, fusion proteins, antibody fragments, bispecifics among other biological formats
• Simple transfer to any CDMO or to our own manufacturing stream
• Capacity available today